Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | NPY1R | P25929 | 1/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 13/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 13/20 | 0.55 |
| ▸ | PDE4A | P27815 | 6/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353452 | 0.92 | SMN1; SMN2 (0.81) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL9687996 | 0.85 | SMN1; SMN2 (0.70) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL8302890 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL930230 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL11035016 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL2846257 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL6331085 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL10556720 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL7273533 | 0.83 | SMN1; SMN2 (0.68) | SMN1; SMN2KCNH2LMNAMAPTNPY1R | |
| SCHEMBL2798028 | 0.82 | SMN1; SMN2 (1.00) | SMN1; SMN2KCNH2LMNAMAPTNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316836-A1 | Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acetylcholine receptors | Abbott Laboratories (US) | 2011-05-04 | — | — | EP | disclosed |
| EP-2308875-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives as .alpha.7 nAChR modulators | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2010-03-11 | — | — | US | disclosed |
| US-7655657-B2 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| WO-2008108602-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008108602-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DONG-A PHARM. CO., LTD. (KR) | 2008-09-12 | — | — | WO | disclosed |
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
| EP-1534700-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | ABBVIE INC. | 2005-05-12 | — | — | US | disclosed |
| WO-2005028477-A1 | SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS | ABBOTT LABORATORIES (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
| WO-2004018448-A1 | NOVEL THIOPHENE DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | WARNER-LAMBERT COMPANY LLC (US) | 2004-03-04 | — | — | WO | disclosed |
| EP-1394159-A1 | New thiophene derivatives, process for their preparation and pharmaceutical compositions containing them | Warner-Lambert Company LLC (US) | 2004-03-03 | — | — | EP | disclosed |
| US-4117130-A | 6-PHENYL-1,2,4-TRIAZOLO(4,3-B)PYRIDAZINES | AMERICAN CYANAMID COMPANY (US) | 1978-09-26 | — | — | US | disclosed |
| US-4112095-A | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents | AMERICAN CYANAMID COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4092311-A | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates | AMERICAN CYANAMID COMPANY (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137204-A1 | Fused bicycloheterocycle substituted quinuclidine derivatives | CHRNA1, CHRNA7, CHRNA2 | SMN1; SMN2 1169/4885KCNH2 197/4885LMNA 1140/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | SMN1; SMN2 819/4885KCNH2 340/4885LMNA 1830/4885 |
| US-20100063041-A1 | NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PPARA, PPARG, PPARD | SMN1; SMN2 4266/4885KCNH2 3129/4885LMNA 2591/4885 |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | SMN1; SMN2 3494/4885KCNH2 2889/4885LMNA 3541/4885 |
| US-20050101602-A1 | For example, 3-(6-phenyl-pyridazin-3-yl)-3,8-diaza-bicyclo[3.2.1]octane; for treatment or prevention of conditions and disorders related to nAChR activity, and more particularly alpha 7 nAChR activity, such as attention deficit disorder, attention deficit hyperactivity disorder, Alzheimer's disease | CHRNA7, CHRNA2, CHRNA6 | SMN1; SMN2 1186/4885KCNH2 765/4885LMNA 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.